Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system
Jiongrui Cao, Li Peng, Jin Yang, Gang Yin, Ping Ke, Jifa Zhang, Min Su, Yun Gao, Yuehui Zhang · 2026
Read Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system by Jiongrui Cao, Li Peng, Jin Yang, Gang Yin, Ping Ke, Jifa Zhang, Min Su, Yun Gao, Yuehui Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13318663.txt.
Description
Jiongrui Cao and co-authors offer a 2026 pharmacovigilance analysis of two cancer immunotherapy drugs. They compare ipilimumab plus nivolumab against nivolumab alone in lung cancer. The focus is severe kidney and pancreas side effects. Reports came from the United States FDA adverse event database.
The dataset covered reports from early 2004 to mid 2025, totalling 2,292 reports. Combination therapy showed strong signals for glomerular kidney injury. Nephrotic syndrome carried a reporting odds ratio of 37.25 in their analysis. Pancreatic harm also signalled strongly for the combination. Median onset was 73 days for kidney events and 84 days for pancreas events in that group. The authors urge closer organ monitoring than standard checks provide.
Catalog record
| CREATOR | Jiongrui Cao, Li Peng, Jin Yang, Gang Yin, Ping Ke, Jifa Zhang, Min Su, Yun Gao, Yuehui Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45971 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |